China Net Finance June 9 (Reporter Liu Xiaofei) In the past weekend, "Yunfeng Xinchuang spent 200 million yuan to participate in China Resources Wandong Dingzeng" news detonated the medical circle. It is understood that this is after the 500 million yuan investment in Guangyao Baiyun Mountain, Ma Yun once again in the field of medical equipment, fully demonstrating the capital's optimism about the market.

The market size has soared 17 times in 14 years.

In recent years, China's medical device industry has developed rapidly due to the aging of the population, the escalation of consumption and the intensive implementation of support policies. According to data from the China Medical Materials Association, in 2004, China's medical device market was only 14.5 billion, and by 2014 this figure had climbed to 255.6 billion, an increase of 16.6 times in 14 years. Some organizations predict that by leveraging the "China Made 2025" Dongfeng, this number is expected to exceed 300 billion this year, and the performance of related listed companies may double.

However, behind the overall prosperity of the medical device industry, problems such as low industry concentration and high dependence on high-end imports have emerged, and have become a bottleneck restricting industry discovery. According to Dongguan Securities, there are about 15,000 medical device manufacturers in China, but 90% of the company's income is less than 20 million yuan. In the current medical institutions, only low-end consumables and black-and-white B-ultrasound products are produced domestically, while high-end medical devices such as CT, MI, and nuclear magnetic resonance are basically monopolized by foreign products. Therefore, for the medical device industry, it is imperative to enhance original technology and original products.

"Made in China 2025" released heavy weight and related concept stocks were sizzled.

In order to improve the core competitiveness of domestic medical equipment, since 2010, the state has intensively introduced support policies for the development of medical devices. Following the “Twelfth Five-Year Plan” to establish the goal of building 40 to 50 high-tech medical device companies, the Ministry of Industry and Information Technology to invest 1.5 billion to set up special funds for supporting medical devices, and the Food and Drug Administration to give priority to the approval of innovative medical devices, the future of medical devices will be outlined. The programmatic document "Made in China 2025" of the annual development blueprint was released in May this year.

"Made in China 2025" proposes to improve the innovation ability and production of medical devices.

At the level of industrialization, we will focus on the development of high-performance medical equipment such as imaging equipment and medical robots, high-value medical consumables such as fully degradable vascular stents, and mobile medical products such as wearable and remote medical treatment. Breakthrough and application of new technologies such as biological 3D printing and induced pluripotent stem cells.